BTG Share Price (BTG)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
BTG Plc	LSE:BTG	London	Ordinary Share	GB0001001592	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+1.00p	+0.12%	828.00p	24,688	08:40:11

Bid Price		Offer Price	High Price	Low Price	Open Price
827.50p		828.00p	829.00p	827.50p	827.50p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Support Services	620.50	-70.60	3.90	212.3	3,207.0

Related Shares
Experian (EXPN), Ferguson (FERG), Nakama (NAK), Kellan Group (KLN)

BTG (BTG) Latest News (1)

BTG News

Date	Time	Source	Headline
23/1/2019	08:54	UKREG	Deutsche Bank AG Form 8.5 (EPT/RI) BTG PLC
22/1/2019	15:20	UKREG	BlackRock Group Form 8.3 - BTG plc
22/1/2019	13:50	UKREG	Form 8.3 - The Vanguard Group, Inc.: BTG plc
22/1/2019	12:08	UKREG	Brewin Dolphin Limited Form 8.3 - BTG plc
22/1/2019	11:26	UKREG	Standard Life Investments Ltd Form 8.3 - BTG plc
22/1/2019	11:08	UKREG	JPMorgan Securities Plc Form 8.5 (EPT/RI)- BTG plc
22/1/2019	10:51	UKREG	BARCLAYS PLC Form 8.5 (EPT/NON-RI) - BTG PLC
22/1/2019	10:26	UKREG	GoldmanSachs International Form 8.5 (EPT/RI)
22/1/2019	09:29	UKREG	Deutsche Bank AG Form 8.5 (EPT/RI) BTG PLC
21/1/2019	21:00	PRNUS	Australian Patient Treated With DC Bead LUMI™, the First Commercially..

More BTG News

BTG Takeover Rumours

BTG (BTG) Share Charts

1 Year BTG Chart

1 Month BTG Chart

Intraday BTG Chart

BTG (BTG) Discussions and Chat

BTG Forums and Chat

Date	Time	Title	Posts
21/1/2019	15:07	BTG	6,036
12/11/2013	08:46	BTG down the tube	6
09/3/2012	07:16	Bright Things	3
10/9/2004	19:24	Varisolve hits the FDA buffer's	6

Add a New Thread

BTG (BTG) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
08:39:59	828.00	11	91.08	AT
08:39:59	828.00	223	1,846.44	AT
08:39:59	828.00	469	3,883.32	AT
08:35:11	828.50	718	5,948.63	AT
08:30:11	828.50	590	4,888.15	AT

View all BTG trades in real-time

BTG (BTG) Top Chat Posts

Date	Subject
22/1/2019 08:20	BTG Daily Update: BTG Plc is listed in the Support Services sector of the London Stock Exchange with ticker BTG. The last closing price for BTG was 827p. BTG Plc has a 4 week average price of 824p and a 12 week average price of 546p. The 1 year high share price is 853p while the 1 year low share price is currently 467.40p. There are currently 387,314,436 shares in issue and the average daily traded volume is 1,290,217 shares. The market capitalisation of BTG Plc is £3,203,090,385.72. Read Full Thread Reply
09/12/2018 17:33	spyder: Very interesting BB. So ... Sand Grove bought 16.2m BTG shares from Woodford. Sand Grove is an ‘event driven’ hedge fund, that is to say, its strategy is to exploit valuation anomalies after a major corporate event such as a bid. Sometimes this will be an equity arbitrage if a perceived mismatch develops between the share price of the buyer and the share price of the seller, but this can’t be the case here as this is an all cash offer. That being the case, SG have spent approximately £134m to make just £1.5m or a 1.3% return. This is a tiny profit and does not reflect the risk of the deal failing to complete. I think we can draw 2 conclusions from this; 1) SG thinks the deal will definitely complete. 2) SG must be betting that another bidder will appear. Of course, they could be wrong, and their strategy will be to buy multiple bid targets and hope that one or two will receive additional offers. Their investment in Laing Infrastructure didn’t work, as this sold after just one bid, I wonder if they will have better luck with BTG? Read Full Thread Follow Reply
09/12/2018 14:22	bargainbob: The parts may be greater than the sum . TIDMBTG RNS Number : 7475J Boston Scientific Corporation 07 December 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, DIRECTLY OR INDIRECTLY, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 December 2018 RECOMMENDED CASH OFFER for BTG plc ("BTG") by Bravo Bidco Limited ("Bravo Bidco") a newly incorporated entity indirectly wholly-owned by Boston Scientific Corporation ("Boston Scientific") Update on irrevocable undertaking given by Woodford Investment Management Limited ("Woodford") On 20 November 2018 the boards of Boston Scientific, Bravo Bidco and BTG announced the terms of a recommended cash offer to be made by Bravo Bidco for the entire issued and to be issued share capital of BTG at a price of 840 pence in cash per BTG Share (the "Rule 2.7 Announcement"). Defined terms in this announcement shall, except where defined in this announcement or the context requires otherwise, have the meanings given to them in the Rule 2.7 Announcement. Included in the Rule 2.7 Announcement were details of irrevocable undertakings to support the offer including that received from Woodford, which gave an irrevocable undertaking in respect of 21,253,256 BTG Shares (the "Woodford Irrevocable"). On 5 December 2018, Boston Scientific and Bravo Bidco announced that Woodford had sold: (i) 600,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Partners LLP acting in its capacity as Investment Manager of Anavio Capital Event Driven UCITS Fund; and (ii) 400,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Master Fund Limited, in each case in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Woodford has subsequently sold 16,200,000 BTG Shares which were subject to the Woodford Irrevocable (the "Transferred Shares") to Sand Grove Capital Management LLP acting in its capacity as discretionary investment manager on behalf of Sand Grove Opportunities Master Fund Ltd, Sand Grove Tactical Fund LP and Investment Opportunities SPC for the account of Investment Opportunities 2 Segregated Portfolio ("Sand Grove"), in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Therefore, Sand Grove has provided an irrevocable undertaking (the "Sand Grove Irrevocable") on substantially the same terms as the Woodford Irrevocable in respect of the Transferred Shares, save that the provisions in the Woodford Irrevocable permitting transfer of BTG Shares in circumstances, other than to the extent required by law, are not contained in the Sand Grove Irrevocable. The total number of BTG Shares which is subject to irrevocable undertakings to support the offer remains unchanged. The Sand Grove Irrevocable (as well as a copy of this announcement) will be uploaded to the Boston Scientific website (hxxp://investors.bostonscientific.com/) shortly. Enquiries: Bravo Bidco / Boston Scientific +1 (508) 683-5565 Susie Lisa (Investor Relations) Barclays Bank PLC, acting through its +44 (0) 20 7623 2323 Investment Bank (financial adviser to Bravo Bidco and Boston Scientific) Douglas Solomon Jed Brody Derek Shakespeare Barclays Bank PLC, acting through its investment bank ("Barclays"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Boston Scientific and Bravo Bidco and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than Boston Scientific and Bravo Bidco for providing the protections afforded to clients of Barclays nor for providing advice in relation to the Acquisition or any other matter referred to in this announcement. This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer, invitation, inducement or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of or exercise rights in respect of any securities, or the solicitation of any vote or approval of an offer to buy securities in any jurisdiction, pursuant to the Acquisition or otherwise nor shall there be any sale, issuance or transfer of any securities pursuant to the Acquisition in any jurisdiction in contravention of any applicable laws. The Acquisition will be implemented solely pursuant to the terms of the Scheme Document (or in the event that the Acquisition is to be implemented by means of a Takeover Offer, the Offer Document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. Any decision, vote or other response in respect of the Acquisition should be made only on the basis of information contained in the Scheme Document. BTG Shareholders are advised to read the formal documentation in relation to the Acquisition carefully once it has been dispatched. This announcement does not constitute a prospectus or prospectus-equivalent document. This announcement has been prepared for the purpose of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom. In accordance with the Code, normal United Kingdom market practice and Rule 14e-5(b) of the Exchange Act, Barclays and its affiliates will continue to act as an exempt principal trader in BTG securities on the London Stock Exchange. The purchases and activities by exempt principal traders which are required to be made public in the United Kingdom pursuant to the Code will be reported to a Regulatory Information Service and will be available on the London Stock Exchange website at www.londonstockexchange.com. This information will also be publicly disclosed in the US to the extent that such information is made public in the United Kingdom. Disclosure requirements of the Code In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at hxxp://investors.bostonscientific.com/, by no later than 12 noon (London time) on 10 December 2018. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END OUPUNVRRWBAURUA (END) Dow Jones Newswires December 07, 2018 02:00 ET (07:00 GMT) Read Full Thread Follow Reply
16/11/2018 11:50	a1ord53: I think that news in October were better than on 13 th of November and share price moved down. And last week and on 13 th share price were like always manipulated.Its why it going back to reality 5-6 £ range. RBC again issued underperform with target price 490 p Varithena value negative CroFab is going to loose 70% revenues due to price reduction Zytiga will halved income Beads no growth anymore according dame Louise( she said growth with market) Who sold at 690-670!should feel very lucky I read transcript of meeting with analysts and answers of dame and cfo were not precise - more likely than concrete. Read Full Thread Follow Reply
15/11/2018 10:58	dp1umb: Why can’t investing be more simple? Positive news = change of momentum = rise in share price. Simple! Read Full Thread Follow Reply
11/11/2018 18:11	bargainbob: What to compare on Tuesday. 4 October 2018 \| 09:45am StockMarketWire.com - Healthcare company BTG guided product sales higher Thursday after including its varicose vein treatment Varithena in its oncology and vascular portfolio. The company said it expected product sales for the combined portfolio to grow by 15%-to-17% this year, up from its previous forecast of 13%-to-15%. In pharmaceuticals, following a good first half, BTG said it expected full-year sales to be around the upper end of the guidance range of flat-to-single digit decline. A better-than-expected first-half performance in pharmaceuticals was driven by DigiFab and Voraxaze, and a good performance from CroFab, BTG said. First-half product sales growth was driven by 'good' performance in Interventional Medicine led by strong growth in radiotherapy treatment TheraSphere and the cryoablation products, the company said. Varithena was expected to become profitable during the 2019/20 financial year with sales expected to peak in the high tens of millions of dollars. Varithena sales would be included within the Vascular product sales line going forwards, BTG said. The company also announced that Chairman Garry Watts was set to retire. At 9:45am: [LON:BTG] BTG PLC share price was +31p at 590.5p Story provided by StockMarketWire.com Read Full Thread Follow Reply
27/10/2018 11:36	spyder: I don’t think anyone expected J&J to win the patent case and as txi mentions, it was always assumed that a favourable outcome would be a (BIG!) bonus, but the default position was a 31.10.18 expiry. On that basis, the share price on Monday should not be affected, but sentiment probably dictates otherwise. It is curious that J&J still feels so strongly about appealing the decision, but I guess it might be a case of “they would say that wouldn’t they”. Read Full Thread Follow Reply
25/7/2018 06:42	bargainbob: One of Britain’s most prominent healthcare companies shot to the top of the FTSE 250 amid speculation that it was being considered a takeover target. BTG closed up 6.7 per cent, or 33¼p, at 529½p as rumours spread of preparations for a bid. The company’s share price has tumbled by 30 per cent since the start of the year, a fall that accelerated amid reports of a £102.8 million operating loss for the year to the end of March. BTG took a £144.7 million charge after delays with Pneumrx, its emphysema treatment, which subsequently failed to win backing from a key panel of the US Food and Drug Administration. Read Full Thread Follow Reply
30/6/2018 16:12	bargainbob: Surprised the Amazon deal did not lift the BTG share price. Read Full Thread Follow Reply
16/6/2017 10:54	aphrodites: Having suffered a DVT myself a couple of years ago in my right leg and with a vein from my knee to my groin now blocked for life, I am probably more aware than most about the advantages the treatment with the EKOS system will provide to the medical world. The present treatment to unblock veins is very primitive and the success rate very, very low indeed. The damage caused to the valves in veins is irreparable unless the blockage is cleared very quickly. The market for the treatment of DVTs is massive and contrary to general opinion the condition is not restricted just to the elderly. I am reliably informed by an air hostess that a young lady of 34 y.o.a suffered a DVT on a flight and actually died on the plane. DVT's are very common indeed. I did have the statistics somewhere but cannot put my hands on them. Maybe someone else can provide. The announcement today has in my opinion far greater implications to the BTG share price than is fully appreciated and I am surprised the price is not back over £7 and moving higher. But it is a Friday. Obviously we will have to wait for the analysts to digest the news and get the blue pencils out next week. Have a good weekend everyone. Onwards and upwards. Read Full Thread Follow Reply
21/6/2015 11:08	spyder: Here are my thoughts on what is happening with the BTG share price, for what they are worth. I suggested in posts to this board several times in the last few months, and most recently at around the time of the results, that the BTG share price was approaching very dangerous chart territory. If it failed to rally, then there would be no support for the shares going forward. Unfortunately, I didn’t “put my money where my mouth was”, because subsequent events proved my comments to be correct and the shares have dropped approximately 20% in the last month or so. I’m afraid the news doesn’t get any better, as, again looking at the chart, this share only has one way to go, and it will continue falling. There could be support at £6.00, and again at £5.00, but I won’t be around to see £5.00 tested if that were to happen and I have an opportunity to exit. To those of you who think charts are nonsense and it is all about the fundamentals, I say that the charts have called it absolutely right so far, in spite of broadly unchanged fundamentals. Indeed, looking at BTGs own forecasts, and almost universally those of the analysts, the outlook remains a positive as ever, so why the freefall? And where are the value buyers? The next few weeks will be a classic test of predicting share price by chart vs fundamentals. If the chart wins, we are heading lower, perhaps significantly. If the fundamentals are to be believed, then value investors should pile in before long. My own strategy is to continue holding, because my investment timeframe is 5 to 10 years, so perhaps one day this will be seen as just another pothole on the road to the FTSE 100. HOWEVER, if the shares fall to £5.80 and linger for more than a day or so, I’m out. Unfortunately I have seen too many extremely successful shares tank for no reason given the fundamentals, only to see that the fundamentals turned out to be hot air. The market (and the chart) usually (but not always!) knows best. Read Full Thread Follow Reply

BTG share price data is direct from the London Stock Exchange

Your Recent History

LSE

BTG

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190123 08:58:38